Landmark study with PCSK9 inhibitor will change clinical practice
Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USAPCSK9 Expert Opinions According to prof. Eric Bruckert, FOURIER is a landmark study that will change clinical practice, especially for patients with the highest risk.
FOURIER: PCSK9 inhibition decreases CV events in high-risk patients 00:25
Good safety profile, also with respect to cognitive function 00:58
In clinical practice, which patients could benefit from treatment? 01:37
Landmark study will change practice 02:50
Educational information
This educational video is part of a series of PCSK9 Expert Opinions that are aimed to provide different perspectives and opinions from international experts in this field and may provide support with the interpretation and translation of new findings towards implications for clinical practice
The educational content reflects the personal opinion of the experts and is recorded as an independent educational service by PACE-CME
Faculty & Disclosures
Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France
Funding
Funding was provided by an unrestricted educational grant from Amgen